Stock Ticker

  • Loading stock data...

Arrowhead Research Corp (NASDAQ:ARWR)’s ARC-520 Data Disappoints

Boston, MA 10/09/2014 (wallstreetpr) – Arrowhead Research Corp (NASDAQ:ARWR) experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more than 40%. In the phase II study conducted, the experimental drug ARC-520 resulted in a 0.3 log reduction in HBsAG when dosed at 2 mg/kg. HBsAG indicates the presence of hepatitis virus in the human body.

The expectations and performance

The treatment result came lower compared to investors expectations. In August, Arrowhead Research Corp (NASDAQ:ARWR) hinted that the reduction from therapy was closer to 1 log. However, the revealed data of 0.3log is much lower than 1-log reduction. The data released on ARC-520 was contained in a later-breaker abstract for AASLD annual meeting. It is scheduled to be held in November. A Phase II study of Arrowhead’s experimental drugARC-520 is ongoing. As of now, Arrowhead is testing with higher doses of ARC-520. It needs to be seen if the higher doses can have a positive impact or not. Arrowhead Research Corp (NASDAQ:ARWR) has yet not disclosed the results from higher doses treatment of ARC-520.

The study

The impact of ARC-520 is seen by measuring the change of HBsAg decline from baseline in percentage terms. The patients who were treated with ARC-520 in cohort 1, mean nadir came at -39% with a mean change of -31% on day 85. The patients who were treated with ARC-520 in cohort 2, mean nadir HBsAg came at – 51%with a mean change of -22% on day 85. If the results in cohort 2 are analyzed, the reduction in HBsAG measured in percentage terms was statistically significant versus placebo for three days through 43 post dose.

For the first time, a reduction in HBsAg resulted through RNA interference has been displayed in chronic HBV patients. A specific formula is used to calculate the change in HBsAg decline from baseline and to convert it into a log reduction.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at [email protected] or follow Nicholas Kitonyi @nmaithyak on Twitter.



  • Recent Stories

    SignUp Now For Our Featured Newsletter

    Sign Up To Get Our Latest Stocks Alerts